Entera Bio Ltd.

ENTX

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001638097

SEC filings (opens in a new tab)

No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Entera Bio Ltd. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021 All holders in Q3 2021

13F holders of ENTX: Q3 2021 compared with Q4 2021
Measure	Q3 2021	Q4 2021	Change
Holders	14	12	−2
Shares	5.67M	5.66M	−9.73K (−0.2%)
Value	$26.7M	$15.9M	−$10.8M (−40.4%)

New holders (2)

Institutions that held Entera Bio Ltd. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to ENTX in Q4 2021
Institution	Shares	Value	% of portfolio
Renaissance Technologies LLC	40,100	$113.0K	0.00%
Altium Wealth Management LLC	11,830	$33.0K	0.00%

Sold out (4)

Institutions that held Entera Bio Ltd. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of ENTX in Q4 2021
Institution	Shares, Q3 2021	Value, Q3 2021
Millennium Management LLC	18,839	$89.0K
Jane Street Group, LLC	11,563	$54.0K
Royal Bank of Canada	1,894	$9.00K
UBS Group AG	565	$3.00K